Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:1127 (2 June), doi:10.1136/bmj.39226.476678.3A
| The first 150 words of the full text of this article appear below. |
Fitzmaurice and Murray make a compelling case for implementing the guidelines on thromboprophylaxis from the National Institute for Health and Clinical Excellence (NICE).1 However, many orthopaedic surgeons would profess to a different point of view.
Firstly, there is currently no evidence from published studies that thromboprophylaxis reduces mortality in patients undergoing elective hip or knee replacements. Secondly, there is much concern regarding the attempted prevention of what the authors themselves call a "silent" disease. While orthopaedic surgeons have not traditionally been seen as the pioneers of holistic medicine, we are reticent to expose our patients to increased risks from treatment for a condition only identified by a radiological test. The NICE guidelines own statistics emphasise this point by documenting the incidence of venous thromboembolism (VTE; radiologically diagnosed deep vein thrombosis and pulmonary embolism) after hip replacement without prophylaxis as 44% and the symptomatic VTE incidence in the same group as
Tim N Board, lecturer in orthopaedics, Martyn L Porter, consultant orthopaedic surgeon
Hip Centre, Wrightington Hospital, Wigan WN6 9EP
tim@timboard.co.uk